SENP7 mediates deSUMOylation and deubiquitination of SP1 to promote lung adenocarcinoma progression and chemoresistance Authors: Zhen Zhang, Qin Huang, Zi-Mei Peng, Xiao-Jian Han, Tao Wang Published: 2026 ABSTRACT Highlights•SENP7 protein is markedly expressed in LUAD, with a strong correlation to disease progression and adverse patient prognoses.•The depletion of SENP7 substantially impedes LUAD progression in both in vitro and in vivo.•SP1 is a bona fide target of SENP7, with SENP7-mediated deSUMOylation, deubiquitination, and stabilization of SP1 being essential for LUAD development and chemoresistance.Keywords: LUAD, SENP7, SP1, deSUMOylation Introduction Lung cancer remains a critical global health challenge due to its high morbidity and mortality rates. Non-small cell lung cancer (NSCLC), which accounts for approximately 85% of lung cancer cases, is associated with a poor prognosis [1]. Lung adenocarcinoma (LUAD) represents a predominant subtype of NSCLC. Despite advancements in LUAD therapies, there is a pressing need to identify novel therapeutic targets for patients who exhibit resistance or non-responsiveness to current treatment modalities. Post-translational SUMOylation is a prevalent mechanism for regulating protein activity within cells. Analogous to ubiquitination, SUMOylation involves a multi-step enzymatic cascade comprising three ubiquitination enzymes: the E1 activating enzyme, the E2 conjugating enzyme, and the E3 ligase [2]. This modification can be reversed by deSUMOylating enzymes, which cleave the isopeptide bond between SUMO and the target lysine residue [3]. In humans, four SUMO isoforms are encoded by distinct genes: SUMO1, SUMO2, SUMO3, and SUMO4 [4]. Notably, the mature forms of SUMO2 and SUMO3 share approximately 97% sequence identity and are frequently referred to as SUMO2/3, whereas they exhibit only about 47% sequence identity with SUMO1 [5]. The SENP protease family represents the principal group of deSUMOylating enzymes in human cells and comprises six members: SENP1, SENP2, SENP3, SENP5, SENP6, and SENP7 [6]. Within this family, SENP6 and SENP7 are the most divergent, characterized by lower sequence identity in their catalytic domains and the presence of extended unstructured protein chain insertions within the catalytic domain [7]. SENP6 and SENP7 exhibit a preference for SUMO2/3 conjugates in terms of isoform specificity [8]. Recent studies have implicated SENP7 in various human diseases, including cancer. For example, in colorectal cancer, SENP7 promotes B-cell (Breg) differentiation and facilitates immune evasion by activating SIRT1 expression through deSUMOylation [9]. Further research in colon cancer suggests that SENP7 overexpression protects cancer cells from hypoxia and glucose deprivation, which is associated with a poor prognosis for patients [10]. However, the potential role of SENP7 in LUAD remains to be elucidated. Specificity protein 1 (SP1) is a pivotal transcription factor that plays a critical role in various biological processes, including cellular proliferation, differentiation, apoptosis, and tumorigenesis. SP1 regulates the expression of a multitude of genes by binding to GC-rich sequences within gene promoter regions. In oncogenesis, SP1 overexpression is significantly associated with the initiation and progression of diverse cancer types [11]. For instance, SP1 binds to the promoter region of the P4HA2 gene, inducing its expression and thereby promoting the progression and metastasis of colorectal cancer. Elevated levels of P4HA2 correlate with poor prognosis, underscoring the importance of SP1 in the transcriptional regulation of P4HA2 and its critical role in colorectal cancer [12]. Additionally, in the context of LUAD, our previous research has demonstrated that SP1 facilitates cancer progression by modulating the expression of UBE2N. High expression levels of SP1 and UBE2N are strongly linked to adverse clinical outcomes in patients, emphasizing the substantial role of SP1 in cancer pathogenesis [13]. In the context of cancer progression, SP1 undergoes a diverse array of post-translational modifications, including phosphorylation, O-linked glycosylation, acetylation, SUMOylation, and ubiquitylation, which target it for proteasome-mediated degradation pathways [11]. For instance, SENP3 modulates overall protein turnover and SP1 levels by counteracting SUMO2/3-mediated ubiquitination and degradation in gastric cancer [14]. In hepatocellular carcinoma, the deubiquitinating enzyme USP39 promotes tumor growth by stabilizing SP1 through the removal of ubiquitin [15]. However, the role of post-translational modifications of SP1, particularly SUMOylation, in the progression of LUAD remains inadequately understood. This study aims to elucidate the role of SENP7 in LUAD, with a focus on its impact on disease progression and chemotherapy resistance through the regulation of SP1 deSUMOylation. Such insights could provide novel perspectives and potential therapeutic targets for the diagnosis and treatment of LUAD. By comprehensively investigating the interaction mechanism between SENP7 and SP1, this research seeks to uncover new insights and directions for LUAD treatment strategies. Materials and methods Database analysis The expression data for the SENP7 gene from the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) samples were obtained via the UCSC Xena platform [16] and subsequently visualized using GraphPad Prism software. Protein expression data for SENP7 in LUAD and normal samples from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) cohort were analyzed utilizing the UALCAN platform [17]. The relationship between SENP7 expression and the prognosis of LUAD patients was assessed using the Kaplan–Meier plotter (KM plotter) database [18]. The correlation between SENP7 and SP1 protein expression was examined through the LinkedOmics platform [19]. Tissue microarray and IHC staining Tissue microarrays comprising 94 cases of human LUAD and 86 cases of adjacent non-cancerous tissues were sourced from Shanghai Outdo Biotech Co., Ltd., China. Informed written consent for the use of clinical information and tissue samples was obtained from all participants. Immunohistochemical (IHC) staining and evaluation were conducted as previously described [20], employing a 1:200 dilution of an anti-SENP7 antibody (Invitrogen, PA5-99191). Cell culture BEAS-2B, A549, H1299, and cisplatin-resistant A549 cells (A549CDDP) were acquired from Fuheng Biological Technology Co. Ltd. (Shanghai, China). BEAS-2B cells were cultured in DMEM medium supplemented with 10% fetal bovine serum in a 5% CO2 incubator at 37°C. A549 and H1299 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum in a 5% CO2 incubator at 37°C. A549CDDP cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 0.5 ug/ml CDDP in a 5% CO2 incubator at 37°C. Western blotting Western blotting was conducted as previously detailed [20], employing a 1:1000 dilution of the following antibodies: anti-SENP7 (Thermo Fisher Scientific Inc, A302-995A), anti-SP1 (Proteintech, 21962-1-AP), anti-RNF4 (Proteintech, 17810-1-AP), anti-Bcl-2 (CST, 15071S), anti-Cleaved Caspase-3 (CST, 9661S) and anti-β actin (Santa Cruz, sc-47778). Lentiviral knockdown and overexpression systems Specific short hairpin RNAs (shRNAs) targeting SENP7 (shSENP7-1 sequence: GTCATCTCTCTAGACCATAAA; shSENP7-2 sequence: GGCAACTCAAAGTTATGTT) were annealed and subcloned into the pLV-H1-EF1α-puro vector (Biosettia, USA). Similarly, shRNAs specific to RNF4 (shRNF4 sequence: GACAAGCTCAGAAGCGAACTC) were annealed and subcloned into the pLV-shRNA-Hygro vector (Inovogen, China). The overexpression SP1 (OE-SP1) lentiviral vector plasmid was constructed as described as previously described [20]. Lentiviral vectors, along with packaging plasmids, were transfected into HEK293T cells using Lipofectamine 2000 reagent (Invitrogen) to produce lentiviruses. Cell proliferation assay Cell proliferation was assessed through CCK-8, colony formation, and EDU incorporation assays, all performed as previously described [20]. RNA extraction and quantitative RT-qPCR RNA extraction and quantitative RT-qPCR were conducted as previously outlined [20]. GAPDH served as the normalization control. The primer sequences employed for qPCR were as follows: SP1-Forward: 5‘-AGTTCCAGACCGTTGATGGG-3’, SP1-Reverse: 5‘-GTTTGCACCTGGTATGATCTGT-3’; GAPDH-Forward: 5’-GGAGCGAGATCCCTCCAAAAT-3’, GAPDH-Reverse: 5’-GGCTGTTGTCATACTTCTCATGG3’. Ubiquitination assay Cells were transfected with HA-ubiquitin plasmids and subsequently treated with the proteasome inhibitor MG132 for 6 h. Cell lysates were prepared using RIPA buffer and incubated with an anti-SP1 antibody (Proteintech, 21962-1-AP) at 4°C overnight. The resulting immunoprecipitates were subjected to Western blot analysis utilizing a 1:1000 dilution of anti-HA-Tag antibody (CST, 3724S). SUMOylation assay Cells were transfected with SUMO3 plasmids and treated with MG132 for 6 h. Lysates were prepared in RIPA buffer and incubated with the anti-SP1 antibody (Proteintech, 21962-1-AP) at 4°C overnight. The immunoprecipitates were then analyzed via Western blotting assays using 1:1000 dilution of anti-SUMO2/3 antibody (CST, 4971T). Co‑immunoprecipitation assay Cells were collected and lysed using RIPA buffer on ice for 30 min. Subsequently, the cell lysates underwent preclearance with protein G Dynabeads (Invitrogen) and were incubated with either the primary antibody or IgG at 4°C overnight. This was followed by a 2-h incubation with protein G Dynabeads (Invitrogen). The beads were washed thrice with lysis buffer, and the resulting immunoprecipitates were subjected to western blotting analysis. Drug dose response curves LUAD cells were plated at a density of 3 × 103 cells per well in 96-well plates and exposed to CDDP (Selleck) at specified concentrations for 48 hours at 37°C in a 5% CO2 atmosphere. Post-treatment, 10 μL of CCK8 solution (DOJINDO) was added to each well and incubated for 2 hours at 37°C. Optical density (OD) values were then measured at 450 nm using a Multiskan Sky (Thermo Fisher Scientific). Inhibition curves and IC50 values were subsequently calculated using GraphPad Prism 9 software. Immunofluorescence staining assay LUAD cells were seeded at a density of 3 × 104 cells per well in 24-well plates and exposed to cisplatin (CDDP) (Selleck) at the specified concentration for 24 h at 37°C in a 5% CO2 atmosphere. Post-treatment, the cells were fixed in methanol for 20 min, followed by blocking with 5% goat serum for 1 h at room temperature. The cells were then incubated with an anti-γH2AX antibody (CST, 9718S) at a 1:200 dilution at 4°C overnight. Subsequently, the cells were treated with CoraLite594-conjugated Goat Anti-Rabbit IgG (Proteintech, SA00013-4) for 1 h at room temperature and counterstained with DAPI for 3 min. The labeled nuclei were visualized using a fluorescence microscope. Tumor xenograft experiments The experimental procedures involving mice in this study received ethical approval from the Ethics Committee of Jiangxi Provincial People’s Hospital. Six-week-old male NOD-SCID mice were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. The shCtrl/A549,shSENP7/A549,shSENP7+OE-SP1/A549, shCtrl/A549CDDP,shSENP7/A549CDDP and shSENP7+OE-SP1/A549CDDP cells (1 × 106 cells in 100μL PBS) were suspended in phosphate-buffered saline (PBS) and inoculated into the left groins of the NOD-SCID mice. After 30 days, the mice were euthanized, and the tumors were excised, weighed, and documented through photography. To investigate tumor chemoresistance, ten days following tumor cell inoculation, the mice received intraperitoneal injections of cisplatin (CDDP) at a dosage of 3 mg/kg every other day for an additional three weeks. Subsequently, the mice were euthanized, and the tumors were excised, weighed, and photographed. Statistical analysis Data analysis was conducted using GraphPad Prism 9 (GraphPad Software Inc) and SPSS version 22 (SPSS Inc). Experimental data are presented as means ± standard deviation (SD) from three independent experiments. Spearman’s rank correlation test was utilized to evaluate the correlation of gene expression in tissue samples. Statistical differences were determined using either Student’s t-test or the Mann-Whitney test, as appropriate. Survival analysis was performed employing the Kaplan-Meier method and log-rank tests. A P-value of less than 0.05 was considered indicative of statistical significance. The correlation analysis was assessed using the r-value. Results SENP7 is highly expressed in LUAD and correlated with poor prognosis of LUAD patients To elucidate the role of SENP7 in the progression of LUAD, we initially investigated its aberrant expression in LUAD utilizing the TCGA and GTEx datasets accessed through the UCSC Xena browser. As illustrated in Fig. 1A, our findings demonstrate that SENP7 expression is markedly elevated in LUAD samples compared to normal lung tissues. Consistently, analysis of data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) via the UALCAN platform corroborates that SENP7 protein levels are increased in LUAD relative to normal lung tissues (Fig. 1B). Importantly, survival analysis using the KM plotter database revealed an inverse correlation between SENP7 expression and overall survival in LUAD patients (Fig. 1C). To substantiate these findings, we conducted immunohistochemistry analyses to assess SENP7 expression in human LUAD and adjacent para-carcinoma tissues. The results indicate that SENP7 expression is significantly elevated in LUAD tissues compared to para-carcinoma tissues (Fig. 1D and 1E). The 94 LUAD tissue samples were stratified into groups with low and high SENP7 expression based on their expression levels (Fig. 1F). Subsequent survival analysis indicated that patients exhibiting higher SENP7 expression experienced poorer overall survival outcomes (Fig. 1G). In summary, the findings suggest that SENP7 is overexpressed in LUAD and correlates with poor prognosis in patients. SENP7 is highly expressed in LUAD and correlated with poor prognosis of LUAD patients. A. Analysis of SENP7 gene expression was conducted on LUAD and normal lung tissues from the TCGA TARGET GTEx cohort, with a significance of ***P < 0.001. B. The UALCAN website's CPTAC data reveals that SENP7 protein expression is higher in LUAD than in normal lung tissues. **P < 0.01. C. The association of SENP7 expression with overall survival in LUAD patients was examined using KM plotter. D, E. SENP7 expression was measured using immunohistochemistry in LUAD and adjacent normal tissues. Scale bars, 500 μm and 50 μm. r = 0.340, P < 0.001. F. Representative IHC staining images showing SENP7 in LUAD tissues. Scale bars, 500 μm and 50 μm.G. Elevated levels of SENP7 are linked to lower overall survival rates in LUAD patients. Log-rank P < 0.001. Inhibition of SENP7 reduces LUAD progression To confirm SENP7′s role in LUAD progression, its protein expression levels were assessed in LUAD cell lines (A549 and H1299) and compared to normal cell lines (BEAS-2B). The analysis revealed that SENP7 expression was relatively low in BEAS-2B cells but significantly elevated in A549 and H1299 cells (Fig. 2A). Subsequently, A549 and H1299 cells were transduced with a lentivirus encoding shRNAs targeting SENP7 (shSENP7-1 and shSENP7-2) or a control shRNA (shCtrl). The application of specific shRNAs resulted in a marked reduction in SENP7 protein levels (Fig. 2B). The impact of SENP7 on the proliferative capacity of LUAD cells was then assessed using CCK-8, colony formation, and EDU incorporation assays. Data from Fig. 2C-2L demonstrated a significant reduction in cell proliferation upon SENP7 knockdown in A549 and H1299 cells. Collectively, these results underscore the critical role of SENP7 in LUAD progression and suggest that targeting SENP7 may serve as an effective strategy to impede LUAD development. Inhibition of SENP7 reduces LUAD progression. A. The SENP7 protein expression in lung/brunch epithelial cells (BEAS-2B) and LUAD cells (A549 and H1299). B. Verification of SENP7 knockdown in A549 and H1299 cells using Western blot analysis. C-L. The CCK8 assay (C, D), clonogenic assay (E-H), and EDU incorporation assay (I-L) were used to evaluate the proliferation of A549 and H1299 cells after SENP7 knockdown. ***P < 0.001, **P < 0.01, *P < 0.05. SENP7 mediates the deubiquitination and stabilization of SP1 protein in LUAD Subsequently, we examined the mechanism through which SENP7 may regulate the progression of LUAD. Previous studies suggest that SENPs predominantly affect biological functions by modulating the transcriptional activity of transcription factors [14,[21], [22], [23], [24], [25], [26]]. This prompted us to investigate whether SENP7 influences LUAD progression by regulating transcription factors. Notably, our prior research identified SP1 as a critical transcription factor in LUAD progression [13], leading us to hypothesize that SENP7 might exert its effects on LUAD progression through the regulation of SP1. To explore this hypothesis, we initially assessed the relationship between SENP7 and SP1 protein expression levels using the LinkedOmics online platform. The correlation analysis revealed a positive association between SENP7 and SP1 protein expression in LUAD samples (Fig. 3A), implying that SENP7 may modulate SP1 protein expression. To validate this observation, we performed immunoblotting assays on A549 and H1299 cell lines, with and without SENP7 knockdown. The results demonstrated that the knockdown of SENP7 using specific shRNAs led to a reduction in SP1 protein levels (Fig. 3B and 3C). Furthermore, the reduction of SENP7 did not alter SP1 mRNA levels (Fig. 3D and 3E); however, it resulted in a rapid decrease in SP1 protein levels at specific time points following treatment with the protein synthesis inhibitor cycloheximide (CHX) in A549 and H1299 cells (Fig. 3F and 3G). This observation suggests that the reduction of SENP7 may facilitate the degradation of SP1 protein. The experimental protocol included the exposure of cells to the lysosomal inhibitor chloroquine (CQ) or the proteasomal inhibitor MG132, both with and without SENP7 depletion. The SENP7 depletion-induced reduction in SP1 protein levels was significantly mitigated by the addition of MG132 (Fig. 3I and 3K), whereas CQ had no effect on this process (Fig. 3H and 3J). Consistent with these findings, the ubiquitination assay revealed that SENP7 reduction led to an increase in SP1 protein polyubiquitination in the presence of MG132 (Fig. 3L and 3M), thereby establishing the role of SENP7 in the deubiquitination and stabilization of SP1 protein via the ubiquitin-proteasome pathway. SENP7 mediates the deubiquitination and stabilization of SP1 protein in LUAD. A. The LinkedOmics platform was used to analyze the relationship between SENP7 and SP1 protein expression in LUAD. B-C. Expression of SP1 and SENP7 protein in shCtrl/A549, shSENP7/A549, shCtrl/H1299, and shSENP7/H1299 cells. D-E. Expression of SP1 mRNA in shCtrl/A549, shSENP7/A549, shCtrl/H1299, and shSENP7/H1299 cells. F-G. Control and SENP7 knockdown LUAD cells were treated with CHX for the indicated time points analyzed by Western blot and quantification of SP1 protein levels normalized to β-actin. H-I. Western blotting of SP1 protein expression in A549 cells after treatment with CQ (H) or MG132 (I) in the presence or absence of SENP7 knockdown. J-K. Western blotting of SP1 protein expression in H1299 cells after treatment with CQ (J) or MG132 (K) in the presence or absence of SENP7 knockdown. L-M. Co-IP analysis of SP1 protein ubiquitination in control and SENP7 knockdown A549 (L) and H1299 (M) cells. SENP7 prevents the ubiquitination of SP1 by deSUMOylating SP1 and abrogating SP1 interaction with RNF4 To investigate the mechanisms through which SENP7 specifically deubiquitinates and stabilizes SP1, we initially confirmed the interaction between SENP7 and SP1 using co-immunoprecipitation (co-IP) assays with endogenous SENP7 or SP1 in A549 and H1299 cells. As illustrated in Fig. 4A and 4B, the co-IP assay results demonstrated a binding interaction between SENP7 and SP1 proteins. Recognizing SENP7′s function as a crucial protease in the removal of SUMO2/3 from modified proteins, we performed co-IP and western blot assays to assess whether SENP7 knockdown influences the SUMOylation level of the SP1 protein. The findings indicated that SENP7 depletion resulted in increased SUMOylation of SP1 in A549 and H1299 cells (Fig. 4C and 4D). Given that RNF4 is known to recognize SUMO2/3-conjugated SP1 and facilitate SUMO2/3-targeted ubiquitination of SP1 [14], we investigated whether SENP7-mediated deconjugation of SUMO2/3 from SP1 disrupts the SP1-RNF4 interaction. A co-IP assay was performed on shCtrl/A549, shSENP7/A549, shCtrl/H1299, and shSENP7/H1299 cell lines, revealing that the interaction between SP1 and RNF4 was significantly enhanced upon SENP7 deletion (Fig. 4E and 4F). This finding confirms that SENP7 disrupts the interaction between RNF4 and SP1. To further elucidate the potential regulatory role of RNF4 in the deubiquitination and stabilization of the SP1 protein mediated by SENP7, we conducted a co-IP assay to assess the impact of RNF4 deletion (shRNF4) on the ubiquitination of the SP1 protein following SENP7 knockdown. The results indicated that the increase in SP1 protein ubiquitination resulting from SENP7 knockdown was mitigated by RNF4 deletion (Fig. 4G and 4H). Collectively, these findings suggest a mechanism whereby SENP7 inhibits the ubiquitination of SP1 by deSUMOylating SP1 and disrupting its interaction with RNF4. SENP7 prevents the ubiquitination of SP1 by deSUMOylating SP1 and abrogating SP1 interaction with RNF4. A-B. The binding of SENP7 to SP1 was detected by Co-IP assay in A549 (A) and H1299 (B) cells. C-D. Co-IP analysis of SP1 protein SUMOylation in control and SENP7 knockdown A549 (C) and H1299 (D) cells. E-F. The binding of SP1 to RNF4 was detected by Co-IP assay in control and SENP7 knockdown A549 (E) and H1299 (F) cells. G-H. Co-IP analysis of SP1 protein ubiquitination in control, SENP7 knockdown, and both SENP7 and RNF4 knockdown A549 (G) and H1299 (H) cells. SENP7 promotes LUAD progression by regulating SP1 protein expression in vitro and in vivo Given that SENP7 deubiquitinates and stabilizes the SP1 protein in lung adenocarcinoma (LUAD), we hypothesize that SENP7 may facilitate LUAD progression through the regulation of SP1 protein expression. To investigate this, we overexpressed SP1 following SENP7 knockdown in LUAD cells (Fig. 5A and 5B). Subsequent analyses using CCK-8, colony formation, and EDU incorporation assays demonstrated that SENP7 knockdown significantly inhibited the proliferation of A549 and H1299 cells. However, this inhibitory effect was notably diminished upon exogenous overexpression of SP1 (Fig. 5C - 5L). To further substantiate these results, we utilized nude mice xenograft tumor models to examine the in vivo effects of the SENP7-SP1 axis on LUAD progression. A549 cells with SENP7 depletion, with or without exogenous SP1 overexpression, were implanted into the left groins of NOD-SCID mice to assess tumor growth. The results indicated a reduction in tumor growth, size, and weight in the SENP7 knockdown group; however, this reduction was mitigated by the reintroduction of SP1 expression (Fig. 5M - 5O). The integration of in vitro and in vivo data indicates that SENP7 may contribute to cancer progression by upregulating SP1 expression in LUAD, highlighting the critical role of the SENP7-SP1 signaling pathway in LUAD advancement. SENP7 promotes LUAD progression by regulating SP1 protein expression in vitro and in vivo. A. The expression of SP1 and SENP7 proteins in shCtrl/A549 and shSENP7/A549 cells, with or without the external overexpression of SP1. B. The expression of SP1 and SENP7 proteins in shCtrl/H1299 and shSENP7/H1299 cells, with or without the external overexpression of SP1. C-L. A549 and H1299 cells proliferation following SENP7 knockdown with or without exogenous overexpression of SP1 was evaluated using CCK8 assay (C, D), clonogenic assay (E-H), and EDU incorporation assay (I-L). ***P < 0.001, **P < 0.01, *P < 0.05. M. Images of xenograft LUAD tumor tissues from the NOD-SCID mice that were injected with SENP7-interfered A549 cells with or without exogenous overexpression of SP1. N-O. Tumor volume (N) and tumor weight (O) in SENP7-interfered A549 cells with or without exogenous overexpression of the SP1 xenograft model. ***P < 0.001. SP1 antagonizes the effect of SENP7 knockdown in regulating LUAD chemoresistance Chemoresistance remains a primary obstacle to successful chemotherapy and a leading cause of mortality among LUAD patients. Consequently, identifying novel targets to enhance the chemosensitivity of LUAD cells is imperative. To address this, protein expression levels of SENP7 and SP1 were evaluated in cisplatin (CDDP)-resistant A549CDDP cells and wild-type A549 cells via Western blot analysis. As illustrated in Fig. 6A, there is an increase in SENP7 and SP1 protein expression in A549CDDP cells compared to A549 cells. To further investigate the potential role of the SENP7-SP1 signaling pathway in LUAD chemoresistance, SP1 was overexpressed following SENP7 knockdown in A549CDDP cells (Fig. 6B). Subsequently, these cells were exposed to cisplatin at specified concentrations. The analysis of IC50 values (Fig. 6C) and colony formation assays (Fig. 6D and 6E) revealed that the depletion of SENP7 significantly potentiated the inhibitory effects of CDDP on cell proliferation in A549CDDP cells. This enhancement, however, was mitigated by the reintroduction of SP1 expression. Moreover, SENP7 knockdown led to an upregulation of the apoptosis marker Cleaved Caspase-3 and a downregulation of the anti-apoptotic marker Bcl-2 in response to CDDP treatment in A549CDDP cells, an effect that was reversed by ectopic SP1 expression (Fig. 6F). Furthermore, the influence of the SENP7-SP1 signaling pathway on CDDP-induced histone H2AX phosphorylation (γH2AX), an indicator of DNA double-strand breaks, was evaluated. The results demonstrated that SENP7 downregulation caused a significant increase in the formation of γH2AX nuclear foci in shSENP7/A549CDDP cells treated with CDDP; however, this increase was notably diminished in cells expressing ectopic SP1 (shSENP7/A549CDDP+OE-SP1) (Fig. 6G and 6H). Additionally, we examined the role of SENP7 and SP1 in modulating LUAD chemoresistance to cisplatin in vivo using a xenograft nude mouse model. Specifically, shCtrl/A549CDDP, shSENP7/A549CDDP, or shSENP7/A549CDDP+OE-SP1 cells were subcutaneously implanted into NOD-SCID mice, followed by administration of CDDP. The findings reveal that CDDP significantly inhibited tumor growth in the shSENP7/A549CDDP group, whereas no such effect was observed in the shCtrl/A549CDDP group. However, the inhibitory effect was diminished in tumors reconstituted with SP1 (Fig. 6I – 6K). Collectively, these results demonstrate that the SENP7-SP1 signaling pathway plays a role in contributing to chemoresistance in LUAD both in vitro and in vivo. SP1 antagonizes the effect of SENP7 knockdown in regulating LUAD chemoresistance. A. The expression of SENP7 and SP1 protein in cisplatin-resistant A549 cells (A549CDDP) and wild-type A549 cells (A549). B. SP1 and SENP7 protein expression in shCtrl/A549CDDP and shSENP7/A549CDDP cells with or without exogenous overexpression of SP1. C. The IC50 values of CDDP in shCtrl/A549CDDP and shSENP7/A549CDDP cells with or without exogenous overexpression of SP1. D-E. The clonogenic capacity of shCtrl/A549CDDP and shSENP7/A549CDDP cells with or without exogenous overexpression of SP1 in response to CDDP (4μg/ml) treatment. ***P < 0.001. F. The expression of Cleaved Caspase-3 and Bcl-2 protein in shCtrl/A549CDDP and shSENP7/A549CDDP cells with or without exogenous overexpression of SP1 in response to CDDP (4μg/ml) treatment. G-H. The formation of γH2AX nuclear foci in shCtrl/A549CDDP and shSENP7/A549CDDP cells with or without exogenous overexpression of SP1 in response to CDDP (4μg/ml) treatment. I. Pictures of tumors in NOD-SCID mice injected with the indicated cells in the presence or absence of CDDP treatment. J-K. Tumor volume (J) and Tumor weight (K) of shCtrl/A549CDDP, shSENP7/A549CDDP, and shSENP7+OE-SP1/A549CDDP groups in response to CDDP treatment. **P < 0.01, *P < 0.05. Discussion As a member of the SUMO-specific protease family, SENP7 plays an essential regulatory role in various pathological conditions and human diseases by removing SUMO2/3 from target proteins. For example, SENP7 is upregulated in intestinal epithelial cells, leading to the expansion of localized proinflammatory γδ T cells and promoting inflammatory responses in inflammatory bowel disease [27]. In addition, SENP7 enhances cGAS activation through the catalysis of cGAS deSUMOylation, thereby stimulating the cGAS/STING/IRF3 pathway, which contributes to microglial pyroptosis and ultimately results in neuronal damage [28]. The role of SENP7 in cancer, however, has been less extensively explored. Research has demonstrated that SENP7 regulates cancer progression in specific tumors such as colorectal cancer [9], breast cancer [29] and glioblastoma [30], either by promoting or inhibiting cancer. Nonetheless, its role in lung adenocarcinoma (LUAD) remains uninvestigated. In this study, we identified SENP7 as a tumor promoter in LUAD. Notably, SENP7 is overexpressed in LUAD, and this high expression is inversely correlated with patient overall survival. The knockdown of SENP7 significantly impedes LUAD progression and enhances sensitivity to cisplatin-based chemotherapy, indicating that SENP7 may serve as a potential therapeutic target for LUAD patients. It is important to highlight that the function of SENP7 extends beyond the direct regulation of protein SUMOylation. SENP7 may also influence cellular signal transduction and gene expression through interactions with other proteins. For example, SENP7 is expressed at elevated levels in prostate tumor specimens harboring SPOP mutations, with its expression being modulated by the E3 ubiquitin ligase SPOP. SPOP functions as a tumor suppressor by facilitating senescence through the degradation of SENP7 [31]. Although our research indicates that SENP7 is significantly overexpressed in LUAD, the regulatory mechanisms underlying this elevated expression remain unclear. Specifically, the identification of the molecules or signaling pathways responsible for the upregulation of SENP7 in LUAD warrants further investigation in future studies. Given that SENPs play a crucial role in the pathogenesis of various diseases, including cancer, atherosclerosis, and cardiovascular diseases, the design and development of novel inhibitors are of paramount importance [32]. A study has reported that the natural compound triptolide downregulates SENP1 expression at both mRNA and protein levels, thereby enhancing sumoylation in prostate cancer cells [33]. Momordin Ic (Mc), a natural inhibitor of SENP1, has been identified as an agent that inhibits SENP1 in multiple myeloma, acute myeloid leukemia, ovarian cancer, and gastric cancer. When combined with chemotherapy, it significantly enhances the sensitivity of tumor cells to chemotherapeutic agents [[34], [35], [36], [37]]. In this study, we demonstrated that specific inhibition of SENP7 can reduce the progression and chemoresistance of LUAD. Consequently, in conjunction with the potential tumor-suppressing effects of other SENPs enzyme inhibitors mentioned above, further investigation into SENP7 inhibitors could provide an effective strategy to inhibit LUAD progression and enhance chemosensitization. The precise mechanism by which SENPs influence RNF4′s substrates destined for the proteasome remains unclear. It is hypothesized that SENPs de-SUMOylate these substrates either prior to or following their arrival at the proteasome [38]. In such cases, SENPs may collaborate with RNF4 to facilitate the removal of SUMOylated proteins. If de-SUMOylation occurs before RNF4′s ubiquitination, SENPs would act antagonistically to RNF4, thereby protecting the substrates from degradation. A study has demonstrated that SENP3 stabilizes SP1 by targeting SUMO2/3 chains on SP1 for shortening, thereby counteracting the effects of RNF4 [14]. In our investigation, we reveal that SENP7 is capable of detaching poly-SUMO2/3 conjugates from SP1 while also removing ubiquitin conjugates. Our findings indicate that SENP7 can counteract the action of RNF4 in a manner similar to SENP3. Furthermore, we show that SENP7′s deconjugation of SUMO2/3 from SP1 impedes RNF4′s ability to recognize and bind to SP1. This supports the role of SENPs as antagonistic regulators of RNF4 substrates and provides biochemical evidence of a direct interaction between SENPs, RNF4, and their shared substrates. Nonetheless, our study has certain limitations, particularly regarding the specific domains and binding sites where SENP7 and SP1 proteins interact, which remain unclear. Future research should focus on an in-depth exploration of these aspects. Moreover, it is important to recognize several limitations inherent in this study. Firstly, functional validation was restricted to the A549 and H1299 LUAD cell lines, with the chemoresistance model being developed exclusively in A549 cells. Although these cell lines represent distinct genetic backgrounds, they do not encompass the full molecular heterogeneity characteristic of LUAD. Consequently, the extent to which our findings can be generalized to other LUAD subtypes remains uncertain. Secondly, the sole reliance on immortalized cell lines constrains our capacity to account for the tumor microenvironment and variability specific to individual patients. Future research should incorporate a broader range of LUAD cell lines, patient-derived primary tumor cells, and organoids to more effectively validate the translational relevance and context-dependent functions of the SENP7-SP1 axis. Furthermore, we recognize that the present chemoresistance experiments were conducted solely using cisplatin, which constitutes only one of the first-line chemotherapeutic agents for lung adenocarcinoma (LUAD). It remains to be determined whether the SENP7-SP1 axis similarly influences sensitivity to other standard treatment regimens, such as gemcitabine or paclitaxel. Considering that various chemotherapeutic agents activate distinct cell death and stress-response pathways, the applicability of our findings to broader clinical scenarios requires further exploration. Future research incorporating a range of chemotherapeutic agents in both sensitive and resistant LUAD models will be crucial to ascertain whether this axis imparts a broad-spectrum resistance phenotype or is specific to cisplatin. While the current study concentrates on the regulation of SP1 protein stability by SENP7, the downstream functional implications of this axis have been comprehensively elucidated in our previous research. We have previously established that SP1 transcriptionally activates UBE2N by directly binding to its promoter, and that UBE2N serves as a pivotal mediator in SP1-driven LUAD progression [13]. In the realm of chemoresistance, UBE2N has been shown to confer resistance to cisplatin by inhibiting apoptosis and influencing DNA damage signaling, as demonstrated in our earlier study [39]. Consequently, the SENP7-SP1-UBE2N axis constitutes a functionally integrated signaling pathway that connects deSUMOylation to chemotherapy response and metastatic progression in LUAD. Conclusions Our current study has elucidated the pivotal role of SENP7 in the progression of LUAD and its contribution to chemoresistance. Furthermore, we have identified SP1 as a definitive target of SENP7, with SENP7 facilitating the deSUMOylation, deubiquitination, and stabilization of SP1 in LUAD. This establishes the SENP7-SP1 axis as a critical regulatory mechanism in LUAD progression and provides a foundation for future therapeutic interventions in LUAD treatment. Ethical approval statement The experiments were conducted in accordance with the ARRIVE guidelines. The animal study was approved by the Ethics Committee of Jiangxi Provincial People’s Hospital. CRediT authorship contribution statement Zhen Zhang: Writing – review & editing, Writing – original draft, Validation, Supervision, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Qin Huang: Validation, Methodology, Investigation. Zi-Mei Peng: Validation, Methodology, Investigation. Xiao-Jian Han: Writing – review & editing. Tao Wang: Validation, Methodology, Investigation. Declaration of competing interest The authors declare that they have no competing interests. Acknowledgements This work is supported by grants from the Ganpo Talent Support Project- Academic and technical leaders training programs in major disciplines (No. 20243BCE51154), the Jiangxi Provincial Natural Science Foundation (No. 20232ACB216013), the National Natural Science Foundation of China (No. 82203342), the Jiangxi Provincial Natural Science Foundation (No. 20224BAB216073), and the Jiangxi Province Key Laboratory of Immunology and Inflammation (No. 2024SSY06251). Footnotes Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.tranon.2026.103019. Supplementary materials References Associated Data Supplementary Materials